PODD vs. TFX, GMED, BAX, NVCR, RMD, SWAV, SOLV, PEN, INSP, and MMSI
Should you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Teleflex (TFX), Globus Medical (GMED), Baxter International (BAX), NovoCure (NVCR), ResMed (RMD), Shockwave Medical (SWAV), NYSE:SOLV (SOLV), Penumbra (PEN), Inspire Medical Systems (INSP), and Merit Medical Systems (MMSI). These companies are all part of the "surgical & medical instruments" industry.
Insulet (NASDAQ:PODD) and Teleflex (NYSE:TFX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.
In the previous week, Teleflex had 11 more articles in the media than Insulet. MarketBeat recorded 17 mentions for Teleflex and 6 mentions for Insulet. Insulet's average media sentiment score of 1.15 beat Teleflex's score of 0.42 indicating that Insulet is being referred to more favorably in the media.
95.6% of Teleflex shares are held by institutional investors. 0.5% of Insulet shares are held by company insiders. Comparatively, 1.4% of Teleflex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Insulet has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Teleflex has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.
Teleflex has higher revenue and earnings than Insulet. Teleflex is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
Insulet received 190 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 65.98% of users gave Insulet an outperform vote while only 59.68% of users gave Teleflex an outperform vote.
Insulet currently has a consensus price target of $243.21, suggesting a potential upside of 42.36%. Teleflex has a consensus price target of $267.50, suggesting a potential upside of 31.32%. Given Insulet's stronger consensus rating and higher probable upside, equities research analysts clearly believe Insulet is more favorable than Teleflex.
Insulet has a net margin of 12.16% compared to Teleflex's net margin of 11.98%. Insulet's return on equity of 32.19% beat Teleflex's return on equity.
Summary
Insulet beats Teleflex on 10 of the 18 factors compared between the two stocks.
Get Insulet News Delivered to You Automatically
Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
